13 completed, 1 active not recruiting. 14 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 14 | Completed 13, Active not recruiting 1 |
Follow retatrutide: new trials by email Literature Review of retatrutide trials Research Report on retatrutide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Investigate the Response of Participants With Type 2 Diabetes Mellitus on Once-Weekly Retatrutide to Hypoglycemia Retatrutide, Placebo - Type 2 Diabetes Mellitus | Phase 1 | Completed | Eli Lilly and Company | 80 | 2025-06-06 | 2026-06-18 |
| A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus Retatrutide, Semaglutide, Placebo - Diabetes Mellitus, Insulin Sensitivity | Phase 1 | Active not recruiting | Eli Lilly and Company | 95 | 2025-06-02 | 2026-10-06 |
| To Investigate the Effect of Retatrutide (LY3437943) on Metoprolol Pharmacokinetics in Healthy Participants Retatrutide, Metoprolol - Healthy | Phase 1 | Completed | Eli Lilly and Company | 30 | 2025-02-03 | 2025-06-05 |
| A Study to Measure Calorie Consumption and Usage in Participants With Obesity Using LY3437943 LY3437943, Placebo - Obesity | Phase 1 | Completed | Eli Lilly and Company | 85 | 2024-03-20 | 2025-09-23 |
| A Study of LY3437943 in Postmenopausal Female Participants Who Are Overweight or Obese LY3437943, Ethinyl Estradiol, Drospirenone - Overweight | Phase 1 | Completed | Eli Lilly and Company | 46 | 2023-09-12 | 2024-07-26 |
| A Research Study Looking at Similarity Between LY3437943 Versions for Different Injection Devices LY3437943, Test, Reference - Healthy | Phase 1 | Completed | Eli Lilly and Company | 57 | 2023-08-29 | 2024-03-29 |
| A Study of LY3437943 in Healthy Participants With a High Body Mass Index LY3437943 - Healthy | Phase 1 | Completed | Eli Lilly and Company | 85 | 2023-07-18 | 2024-10-01 |
| A Study of LY3437943 in Participants With Impaired and Normal Liver Function LY3437943 - Healthy, Hepatic Insufficiency | Phase 1 | Completed | Eli Lilly and Company | 43 | 2023-07-13 | 2025-04-18 |
| A Study of LY3437943 in Healthy Participants and Participants With Impaired Renal Function LY3437943 - Healthy, Renal Insufficiency | Phase 1 | Completed | Eli Lilly and Company | 29 | 2022-11-16 | 2023-10-02 |
| A Study of LY3437943 in Chinese Participants With Obesity Or Overweight LY3437943, Placebo - Overweight, Obesity | Phase 1 | Completed | Eli Lilly and Company | 32 | 2022-10-24 | 2023-08-14 |
| A Drug-Drug Interaction (DDI) Study of LY3437943 in Obese Participants LY3437943, Midazolam, Warfarin - Obesity | Phase 1 | Completed | Eli Lilly and Company | 32 | 2022-07-08 | 2023-04-18 |
| A Study of LY3437943 in Japanese Participants With Type 2 Diabetes Mellitus (T2DM) LY3437943, Placebo - Diabetes Mellitus, Type 2 | Phase 1 | Completed | Eli Lilly and Company | 64 | 2021-05-24 | 2022-08-22 |
| A Study of LY3437943 in Participants With Type 2 Diabetes Mellitus (T2DM) LY3437943, Dulaglutide, Placebo - Diabetes Mellitus, Type 2 | Phase 1 | Completed | Eli Lilly and Company | 72 | 2019-12-18 | 2021-01-20 |
| A Safety Study of LY3437943 Given as a Single Injection in Healthy Participants LY3437943, Placebo - Healthy | Phase 1 | Completed | Eli Lilly and Company | 45 | 2019-03-13 | 2019-08-06 |
Obesity (4) · Diabetes Mellitus, Type 2 (3) · Overweight (3) · Diabetes Mellitus (1) · Hepatic Insufficiency (1) · Insulin Resistance (1) · Renal Insufficiency (1)
United States (8) · Singapore (2) · Austria (1) · China (1) · Germany (1) · Japan (1)